USFDA14 May 2025, 12:51 pm
Zydus Lifesciences Ltd Receives EIR for Ambernath API Manufacturing Facility from USFDA
AI Summary
Zydus Lifesciences Ltd has announced that it has received an EIR (Establishment Inspection Report) from the USFDA for its API (Active Pharmaceutical Ingredient) manufacturing facility located at Ambernath, Maharashtra. The facility was inspected from 10th to 14th February 2025 and received a 'No Action Indicated' (NAI) classification, indicating no objectionable conditions or practices were found. This disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Zydus Lifesciences Ltd receives EIR for its API manufacturing facility from USFDA.
- The facility located at Ambernath, Maharashtra underwent an inspection from 10th to 14th February 2025 with NIL observations.
- The EIR report has classified the facility as No Action Indicated (NAI).
- This disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.